JP2018148931A5 - - Google Patents

Download PDF

Info

Publication number
JP2018148931A5
JP2018148931A5 JP2018124311A JP2018124311A JP2018148931A5 JP 2018148931 A5 JP2018148931 A5 JP 2018148931A5 JP 2018124311 A JP2018124311 A JP 2018124311A JP 2018124311 A JP2018124311 A JP 2018124311A JP 2018148931 A5 JP2018148931 A5 JP 2018148931A5
Authority
JP
Japan
Prior art keywords
variants
locus
dcr3
subject
comprises seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018124311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018148931A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018148931A publication Critical patent/JP2018148931A/ja
Publication of JP2018148931A5 publication Critical patent/JP2018148931A5/ja
Withdrawn legal-status Critical Current

Links

JP2018124311A 2013-05-17 2018-06-29 クローン病に関連するtnfsf15及びdcr3の変異体 Withdrawn JP2018148931A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361824932P 2013-05-17 2013-05-17
US61/824,932 2013-05-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016514143A Division JP6482533B2 (ja) 2013-05-17 2014-05-16 クローン病に関連するtnfsf15及びdcr3の変異体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020096798A Division JP2020127437A (ja) 2013-05-17 2020-06-03 クローン病に関連するtnfsf15及びdcr3の変異体

Publications (2)

Publication Number Publication Date
JP2018148931A JP2018148931A (ja) 2018-09-27
JP2018148931A5 true JP2018148931A5 (cg-RX-API-DMAC7.html) 2019-03-14

Family

ID=51899024

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016514143A Active JP6482533B2 (ja) 2013-05-17 2014-05-16 クローン病に関連するtnfsf15及びdcr3の変異体
JP2018124311A Withdrawn JP2018148931A (ja) 2013-05-17 2018-06-29 クローン病に関連するtnfsf15及びdcr3の変異体
JP2020096798A Withdrawn JP2020127437A (ja) 2013-05-17 2020-06-03 クローン病に関連するtnfsf15及びdcr3の変異体
JP2022093628A Withdrawn JP2022111329A (ja) 2013-05-17 2022-06-09 クローン病に関連するtnfsf15及びdcr3の変異体
JP2024213907A Pending JP2025023316A (ja) 2013-05-17 2024-12-06 クローン病に関連するtnfsf15及びdcr3の変異体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016514143A Active JP6482533B2 (ja) 2013-05-17 2014-05-16 クローン病に関連するtnfsf15及びdcr3の変異体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020096798A Withdrawn JP2020127437A (ja) 2013-05-17 2020-06-03 クローン病に関連するtnfsf15及びdcr3の変異体
JP2022093628A Withdrawn JP2022111329A (ja) 2013-05-17 2022-06-09 クローン病に関連するtnfsf15及びdcr3の変異体
JP2024213907A Pending JP2025023316A (ja) 2013-05-17 2024-12-06 クローン病に関連するtnfsf15及びdcr3の変異体

Country Status (7)

Country Link
US (4) US20160090629A1 (cg-RX-API-DMAC7.html)
EP (3) EP3498867B1 (cg-RX-API-DMAC7.html)
JP (5) JP6482533B2 (cg-RX-API-DMAC7.html)
KR (4) KR20230093538A (cg-RX-API-DMAC7.html)
CN (1) CN105358713B (cg-RX-API-DMAC7.html)
ES (1) ES2894963T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014186750A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
JP2014531210A (ja) 2011-09-30 2014-11-27 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド TL1aに対する抗体およびその使用
WO2014160883A1 (en) 2013-03-27 2014-10-02 Cedars-Sinai Medical Center Treating fibrosis and inflammation by inhibiting tl1a
EP3498867B1 (en) 2013-05-17 2021-09-29 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
EP3337465B1 (en) 2015-08-21 2021-11-24 The Children's Hospital of Philadelphia Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
EP3458466B1 (en) * 2016-05-20 2024-08-07 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
EP3846851A4 (en) * 2018-09-07 2022-09-21 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISORDERS OF THE LYMPHATIC SYSTEM
KR20220088529A (ko) 2019-05-14 2022-06-27 프로메테우스 바이오사이언시즈, 인크. Tl1a 환자 선택 방법, 시스템 및 장치
BR112022004590A2 (pt) * 2019-09-13 2022-06-14 Kyowa Kirin Co Ltd Variante dcr3
PH12023500011A1 (en) * 2020-11-13 2024-03-11 Cedars Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
WO2025038473A1 (en) 2023-08-11 2025-02-20 Paragon Therapeutics, Inc. Tl1a binding antibodies and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009052512A2 (en) 2007-10-19 2009-04-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
SI2257643T1 (sl) 2008-02-19 2018-12-31 The Children's Hospital Of Philadelphia Identifikacija predelov vnetne črevesne bolezni z začetkom v otroštvu in metode za njeno uporabo za diagnozo in zdravljenje te bolezni
WO2010118210A1 (en) * 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
AU2010236568B2 (en) * 2009-04-14 2015-08-27 Société des Produits Nestlé S.A. Inflammatory bowel disease prognostics
EP2630495B1 (en) 2010-10-18 2017-02-08 Nestec S.A. Methods for determining anti-drug antibody isotypes
DK2676137T3 (en) 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
WO2012161856A1 (en) * 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
CA2841416A1 (en) 2011-06-15 2012-12-20 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
EP2565277A1 (en) 2011-09-05 2013-03-06 Progenika Biopharma, S.A. Method for predicting radiographic severity in ankylosing spondylitis
JP2015502740A (ja) 2011-10-21 2015-01-29 ネステク ソシエテ アノニム 炎症性腸疾患の診断を改善するための方法
EP3498867B1 (en) 2013-05-17 2021-09-29 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법

Similar Documents

Publication Publication Date Title
JP2018148931A5 (cg-RX-API-DMAC7.html)
JP2020127437A5 (cg-RX-API-DMAC7.html)
Bang et al. Comorbidities and metabolic derangement of NAFLD
JP2014239695A5 (cg-RX-API-DMAC7.html)
JP2016198116A5 (cg-RX-API-DMAC7.html)
JP2016526875A5 (cg-RX-API-DMAC7.html)
JP2018519508A5 (cg-RX-API-DMAC7.html)
Kong et al. Detection methods of cyprinid herpesvirus 2 infection in silver crucian carp (Carassius auratus gibelio) via a pORF 72 monoclonal antibody
JP2016512214A5 (cg-RX-API-DMAC7.html)
JP2018507254A5 (cg-RX-API-DMAC7.html)
JP2018515071A5 (cg-RX-API-DMAC7.html)
JP2018531892A5 (cg-RX-API-DMAC7.html)
JP2014502848A5 (cg-RX-API-DMAC7.html)
Gutjahr et al. Two monoclonal antibodies against glycoprotein Gn protect mice from Rift Valley Fever challenge by cooperative effects
JP2018504903A5 (cg-RX-API-DMAC7.html)
MA39848A (fr) Agents thérapeutiques de type anticorps se liant à cd147
Morè et al. Current main topics in multiple myeloma
Verma et al. Influence of Th1 versus Th2 immune bias on viral, pathological, and immunological dynamics in SARS-CoV-2 variant-infected human ACE2 knock-in mice
JP2019516104A5 (cg-RX-API-DMAC7.html)
JP2019513346A5 (cg-RX-API-DMAC7.html)
WO2018075633A3 (en) Compositions and methods for detecting or quantifying hepatitis c virus
Imsonpang et al. Confirmatory test of active IHHNV infection in shrimp by immunohistochemistry and IHHNV‐LongAmp PCR
Zhang et al. Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma
Urban‐Chmiel et al. Rapid Detection of Bovine Respiratory Syncytial Virus in P oland Using a Human Patient‐Side Diagnostic Assay
JP2017522890A5 (cg-RX-API-DMAC7.html)